4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents
Conclusions The new imidazolyl hydroxamic acids lend themselves as a possible alternative to SAHA in the therapy of HCC. Even more so since similar 4,5-diarylimidazoles lacking only the hydroxamate functionality were previously shown in animal studies to be well tolerated and orally applicable.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Hepatocellular Carcinoma | Investigational New Drugs | Liver | Liver Cancer | Study | Urology & Nephrology